Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial

Simple item page
dc.contributor.authorKumar, Princy
dc.contributor.authorJohnson, Margaret
dc.contributor.authorMolina, Jean-Michel
dc.contributor.authorRizzardini, Giuliano
dc.contributor.authorCahn, Pedro
dc.contributor.authorWan, Hong
dc.contributor.authorXu, Zhi Jin
dc.contributor.authorMorais, Cristiana
dc.contributor.authorSklar, Peter
dc.contributor.authorGreaves, Wayne
dc.contributor.authorDRIVE-SHIFT Study Group
dc.date.accessioned2024-05-23T23:49:14Z
dc.date.available2024-05-23T23:49:14Z
dc.date.issued2021
dc.descriptionFil: Kumar P. Division of Infectious Diseases and Travel Medicine, Georgetown University Medical Center, Washington, DC; United Stateses_ES
dc.description.abstractBackground: In the primary analysis of the DRIVE-SHIFT trial, switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression of HIV-1 through week 48. Here, we present long-term efficacy and safety outcomes through week 144 of the DRIVE-SHIFT trial. Methods: This phase 3, randomized, open-label trial evaluated switching from a stable antiretroviral regimen to once-daily DOR/3TC/TDF in adults with HIV-1 suppressed for ≥6 months and no previous virologic failure. Participants switched at day 1 [immediate switch group (ISG); n = 447] or week 24 [delayed switch group (DSG); n = 209]. Nine ISG participants who completed week 48 but did not enter extension-1 were excluded from week 144 efficacy analyses. Results: At week 144, HIV-1 RNA <50 copies/mL was maintained in 80.1% of the ISG (351/438) and 83.7% of the DSG (175/209), while 2.7% (12/438) and 4.8% (10/209), respectively, had HIV-1 RNA ≥50 copies/mL (Food and Drug Administration Snapshot approach). Protocol-defined virologic failure after switch occurred in 2.1% of ISG (9/438) and 3.3% of DSG (7/209); no viral resistance to doravirine was detected in 4 participants with samples available. Reductions in fasting lipids were observed at 24 weeks after switch and maintained through week 144. The mean weight change from switch to week 144 was +1.4 kg for ISG and +1.2 kg for DSG. The most common adverse events were nasopharyngitis (16.2%), headache (12.3%), and diarrhea (9.1%). Overall, 4.1% discontinued because of adverse events, and no deaths occurred. Conclusions: These results confirm that switching to once-daily DOR/3TC/TDF is a generally well-tolerated option for maintaining viral suppression in adults considering a change in therapy. Registration: ClinicalTrials.gov NCT02397096.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1097/qai.0000000000002642
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1328
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesJAIDS Journal of Acquired Immune Deficiency Syndromes;2021 Jun 1; 87(2): 801–805.
dc.rightsopenAccesses_ES
dc.subjectHIVes_ES
dc.subjectClinical Triales_ES
dc.titleSwitching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Triales_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1097-QAI.0000000000002642.pdf
Size:
322.06 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos